Synapse - David Straus

Results (125)

The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders

Meeting Abstract

Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save

Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity

Meeting Abstract

O'connor, O.; Hamlin, P. A.; Neylon, E.; Moskowitz, C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Cortelli, B.; Zelenetz, A. D.; Fleisher, M.; more...
Blood (2005)

Fulltext@MSK | Save

Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-Cell lymphomas: Minimal benefit when analyzed by intent to treat

Meeting Abstract

Horwitz, S.; Moskowitz, C.; Kewalramani, T.; Hamlin, P.; Straus, D.; O'connor, O.; Noy, A.; Portlock, C.; Nimer, S.; Palomba, M. L.; more...
Blood (2005)

Fulltext@MSK | Save

Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin((R))) for elderly high risk patients with untreated DLBCL

Meeting Abstract

Hamlin, P. A.; Moskowitz, C. H.; Wegner, B. C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Dumitrescu, O.; Palomba, M. L.; Horwitz, S. M.; O'Connor, O. A.; more...
Blood (2005)

Fulltext@MSK | Save

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

Journal Article

O'Connor, O. A.; Wright, J.; Moskowitz, C.; Muzzy, J.; Macgregor-Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; more...
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Primary mediastinal large B-cell lymphoma: Optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999

Journal Article

Hamlin, P. A.; Portlock, C. S.; Straus, D. J.; Noy, A.; Singer, A.; Horwitz, S. M.; Oconnor, O. A.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
British Journal of Haematology (2005)

Fulltext@MSK | Save

R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy

Journal Article

Halaas, J. L.; Moskowitz, C. H.; Horwitz, S.; Portlock, C.; Noy, A.; Straus, D.; O'Connor, O. A.; Yahalom, J.; Zelenetz, A. D.
Leukemia and Lymphoma (2005)

Fulltext@MSK | Save

Results of a phase II trial of oral bexarotene combined with interferon alfa-2b for patients with cutaneous T-cell lymphoma (CTCL)

Meeting Abstract

Straus, D. J.; Duvic, M.; Kozel, T.; Horwitz, S.; Demierre, M. F.; Myskowski, P.; Maignan, K.; Steckel, S.
Blood (2004)

Fulltext@MSK | Save

Primary Mediastinal Large B cell Lymphoma: Elucidating optimal therapy and prognostic factors; an analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980-1999